Target Market Focus Focus on outreach to oncology and dermatology divisions of mid to large biotech firms and contract research organizations that may be exploring collaborations on alopecia therapies, particularly those with pipeline products for chemotherapy-induced or androgenic alopecia.

Strategic Partnerships Position KaB-103 as a potential external development or clinical collaboration opportunity for companies seeking to expand their portfolio in hair loss therapies, offering complementary mechanisms to existing CIA or AGA programs.

Evidence Build Leverage progression from a startup with a clear alopecia focus to request pilot studies, joint development agreements, or licensing talks, highlighting the market size in androgenic and chemotherapy-induced alopecia and the potential for accelerated timelines.

Resource Leverage Underscore lean team and focused R&D to interested partners as a testbed for outsourcing manufacturing, clinical trial services, or regulatory consulting to scale quickly with partner support.

Technology Fit Identify opportunities to integrate Kanpecia’s tech stack or data capabilities with partner platforms for nonclinical data management, registry collaborations, or real-world evidence generation to de-risk investments.